A pilot study of atomoxetine in young children with attention-deficit/hyperactivity disorder.

Journal Article (Clinical Trial;Journal Article;Multicenter Study)

OBJECTIVE: The purpose of this study was to assess the effectiveness and tolerability of atomoxetine during acute treatment of attention-deficit/hyperactivity disorder (ADHD) in 5 and 6 year olds. METHOD: Twenty two children (male n = 19, 86%) with ADHD were treated with atomoxetine for 8 weeks in a three-site, open-label pilot study. Dosing was flexible, with titration to a maximum of 1.8 mg/kg per day. Parent education on behavior management was provided as part of each pharmacotherapy visit. RESULTS: Subjects demonstrated a mean decrease of 20.68 points (SD = 12.80, p < 0.001)) on the ADHD Rating Scale-IV (ADHD-IV-RS) total score, 10.18 (SD = 7.48, p < 0.001) on the inattentive subscale and 10.50 (SD = 7.04, p < 0.001) on the hyperactive/impulsive subscale. Clinical Global Impression-Severity (CGI-S) was improved in 82% of the children (95% CI, 66-98%) and Children's Global Assessment (CGAS) scores improved 18.91 points on average (SD = 12.20, p < 0.001). The mean final dose of atomoxetine was 1.25 mg/kg per day (SD = 0.35 mg/kg per day). Mood lability was the most commonly reported adverse event (n = 12, 54.5%). Eleven subjects (50%) reported decreased appetite and a mean weight loss of 1.04 kg (SD = 0.80 kg) (p < 0.001) was observed for the group. Vital sign changes were mild and not clinically significant. There were no discontinuations due to adverse events or lack of efficacy. CONCLUSION: Atomoxetine was generally effective for reducing core ADHD symptoms in the 5 and 6 year olds in this open-label study.

Full Text

Duke Authors

Cited Authors

  • Kratochvil, CJ; Vaughan, BS; Mayfield-Jorgensen, ML; March, JS; Kollins, SH; Murray, DW; Ravi, H; Greenhill, LL; Kotler, LA; Paykina, N; Biggins, P; Stoner, J

Published Date

  • April 2007

Published In

Volume / Issue

  • 17 / 2

Start / End Page

  • 175 - 185

PubMed ID

  • 17489712

International Standard Serial Number (ISSN)

  • 1044-5463

Digital Object Identifier (DOI)

  • 10.1089/cap.2006.0143


  • eng

Conference Location

  • United States